Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 1/20 | 0.44 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.40 |
| ▸ | DGAT2 | Q96PD7 | 3/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2114923 | 0.93 | CHRM1 (0.44) | CTSSS1PR2DGAT2CHRM1CHRM2 | |
| SCHEMBL2114310 | 0.88 | CTSS (0.53) | CTSSS1PR2DGAT2USP30 | |
| SCHEMBL2114521 | 0.87 | CTSS (0.44) | CTSSHRH3CHRM1CHRM2CHRM4 | |
| SCHEMBL2610206 | 0.85 | CTSS (0.47) | CTSSCHRM1CHRM2CHRM4 | |
| SCHEMBL2113188 | 0.80 | CHRM1 (0.46) | CTSSHRH3CHRM1CHRM2CHRM4 | |
| SCHEMBL2112400 | 0.80 | PDK2 (0.48) | CTSSS1PR2CHRM1CHRM2CHRM4 | |
| SCHEMBL2710775 | 0.79 | CHRM1 (0.47) | CTSSCHRM1CHRM2CHRM4 | |
| SCHEMBL2610205 | 0.78 | CHRM1 (0.49) | CTSSCHRM1CHRM2CHRM4 | |
| SCHEMBL1583532 | 0.76 | P2RX7 (0.51) | HRH3ENPP2NR1H2HRH1KCNH2 | |
| SCHEMBL2113359 | 0.75 | CTSS (0.53) | CTSSCHRM1CHRM2CHRM4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2630141-A1 | CATHEPSIN S INHIBITOR COMPOUNDS | Eli Lilly and Company (US) | 2013-08-28 | — | — | EP | disclosed |
| US-8227468-B2 | Cathepsin S inhibitor compounds | ELI LILLY AND COMPANY (US) | 2012-07-24 | — | — | US | disclosed |
| US-8227468-B2 | Cathepsin S inhibitor compounds | ELI LILLY AND COMPANY (US) | 2012-07-24 | — | — | US | disclosed |
| WO-2012054315-A1 | CATHEPSIN S INHIBITOR COMPOUNDS | ELI LILLY AND COMPANY (US) | 2012-04-26 | — | — | WO | disclosed |
| WO-2012054315-A1 | CATHEPSIN S INHIBITOR COMPOUNDS | ELI LILLY AND COMPANY (US) | 2012-04-26 | — | — | WO | disclosed |
| US-20120095020-A1 | Cathepsin S Inhibitor Compounds | ELI LILLY AND COMPANY (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120095020-A1 | Cathepsin S Inhibitor Compounds | ELI LILLY AND COMPANY (US) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095020-A1 | Cathepsin S Inhibitor Compounds | CTSS, CTSZ, CTSV | CTSS 1/4885S1PR2 1075/4885DGAT2 3382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.